- Conditions
- Multiple Myeloma
- Interventions
- Plerixafor, bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2016
- U.S. locations
- 5
- States / cities
- Boston, Massachusetts • Hyannis, Massachusetts • Milford, Massachusetts + 2 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 2353–2376
of 12,244
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Multiple Sclerosis
- Interventions
- Active RS-tDCS +At-Home Manual Dexterity Training, Sham RS-tDCS +At-Home Manual Dexterity Training, Manual dexterity training
- Device · Other
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Achromatopsia
- Interventions
- adeno-associated virus vector AAV- CNGA3
- Biological
- Lead sponsor
- MeiraGTx UK II Ltd
- Industry
- Eligibility
- 3 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous/Nonmalignant Condition, Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- aldesleukin, recombinant interferon alfa
- Biological
- Lead sponsor
- Hoag Memorial Hospital Presbyterian
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 1999
- U.S. locations
- 5
- States / cities
- Newport Beach, California • Bloomington, Indiana • Indianapolis, Indiana + 2 more
- Conditions
- Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
- Interventions
- Efprezimod alfa, Placebo, Methotrexate, Tacrolimus
- Drug
- Lead sponsor
- Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021
- U.S. locations
- 4
- States / cities
- Duarte, California • Chicago, Illinois • Hershey, Pennsylvania + 1 more
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndrome
- Interventions
- RPT1G
- Drug
- Lead sponsor
- Remedy Plan, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 2
- States / cities
- New York, New York • Houston, Texas
- Conditions
- Autistic Disorder
- Interventions
- Placebo, RO5028442
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 18 Years to 45 Years · Male only
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2013
- U.S. locations
- 3
- States / cities
- Los Ageles, California • New Haven, Connecticut • The Bronx, New York
- Conditions
- Acute Undifferentiated Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in Remission, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Childhood Acute Lymphoblastic Leukemia in Remission, Childhood Acute Myeloid Leukemia in Remission, Childhood Burkitt Lymphoma, Childhood Chronic Myelogenous Leukemia, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Myelodysplastic Syndromes, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Chronic Myelomonocytic Leukemia, Chronic Phase Chronic Myelogenous Leukemia, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Hepatosplenic T-cell Lymphoma, Intraocular Lymphoma, Juvenile Myelomonocytic Leukemia, Mast Cell Leukemia, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Nodal Marginal Zone B-cell Lymphoma, Noncutaneous Extranodal Lymphoma, Peripheral T-cell Lymphoma, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Refractory Chronic Lymphocytic Leukemia, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Relapsing Chronic Myelogenous Leukemia, Secondary Myelodysplastic Syndromes, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Testicular Lymphoma, Waldenström Macroglobulinemia
- Interventions
- alemtuzumab, total-body irradiation, fludarabine phosphate, cyclosporine, mycophenolate mofetil, allogeneic hematopoietic stem cell transplantation, peripheral blood stem cell transplantation, graft versus host disease prophylaxis/therapy, laboratory biomarker analysis
- Biological · Radiation · Drug + 2 more
- Lead sponsor
- Fred Hutchinson Cancer Center
- Other
- Eligibility
- Up to 74 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2015
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Asthma
- Interventions
- FlutiForm 250/10, SKP-Fluticasone, Flovent Fluticasone HFA
- Drug
- Lead sponsor
- SkyePharma AG
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 438 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008
- U.S. locations
- 21
- States / cities
- Scottsdale, Arizona • Tempe, Arizona • Encinitas, California + 18 more
- Conditions
- Lower Urinary Tract Symptoms, Benign Prostatic Hyperplasia
- Interventions
- MCS-2 15 mg/day, MCS-2 30 mg/day, Placebo
- Drug
- Lead sponsor
- Health Ever Bio-Tech Co., Ltd.
- Industry
- Eligibility
- 40 Years and older · Male only
- Enrollment
- 274 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Chronic Weight Management
- Interventions
- ASC36 tablets, for oral use, ASC36 placebo tablets
- Drug
- Lead sponsor
- Ascletis Pharma (China) Co., Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 86 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Acute Coronary Syndrome (ACS)
- Interventions
- Biomarkers
- Device
- Lead sponsor
- Abbott RDx Cardiometabolic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 18
- States / cities
- Sacramento, California • New Haven, Connecticut • Baltimore, Maryland + 13 more
- Conditions
- Amyotrophic Lateral Sclerosis
- Interventions
- Placebo (Part A), CK-2017357 (Part A), Riluzole 50 MG (Part B), Placebo (Part B), CK-2017357 (Part B)
- Drug
- Lead sponsor
- Cytokinetics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2012
- U.S. locations
- 9
- States / cities
- San Francisco, California • Jacksonville, Florida • Kansas City, Kansas + 6 more
- Conditions
- Multiple Sclerosis
- Interventions
- Feraheme, Gadolinium-based contrast
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 2
- States / cities
- Stanford, California
- Conditions
- Migraine
- Interventions
- Staccato Loxapine, Staccato Placebo
- Drug
- Lead sponsor
- Alexza Pharmaceuticals, Inc.
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 168 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2007
- U.S. locations
- 1
- States / cities
- Wellesley Hills, Massachusetts
- Conditions
- Multiple Sclerosis
- Interventions
- Rebif®
- Drug
- Lead sponsor
- EMD Serono
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Burnout, Professional
- Interventions
- MINDI mindfulness curriculum, Control
- Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- Not listed
- Enrollment
- 358 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Heart Failure
- Interventions
- Vericiguat (BAY1021189) (1.25 mg), Vericiguat (BAY1021189) (5 mg), Placebo
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 456 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2015
- U.S. locations
- 18
- States / cities
- Fountain Valley, California • Wilmington, Delaware • Fort Lauderdale, Florida + 15 more
- Conditions
- Multiple Sclerosis, Neuromyelitis Optica, Demyelinating Autoimmune Diseases, CNS
- Interventions
- Not listed
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 170 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2034
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Breast Cancer
- Interventions
- Quality-of-life Questionnaire
- Behavioral
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Timeline
- 2025 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- HIV Infections, Protease Inhibitor
- Interventions
- Atazanavir Sulphate
- Drug
- Lead sponsor
- Bristol-Myers Squibb
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2006
- U.S. locations
- 1
- States / cities
- Hamilton, New Jersey
- Conditions
- Brain and Central Nervous System Tumors
- Interventions
- temozolomide, Imaging biomarker analysis, Photon Radiation Therapy
- Drug · Other · Radiation
- Lead sponsor
- Massachusetts General Hospital
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2012
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Alzheimer's Disease
- Interventions
- MK-1708, Itraconazole
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 12 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024
- U.S. locations
- 1
- States / cities
- South Miami, Florida
- Conditions
- Alzheimer Disease
- Interventions
- bapineuzumab, placebo
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years to 89 Years
- Enrollment
- 79 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2010
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Encino, California + 14 more